VolitionRx Limited (NYSEAMERICAN:VNRX) Short Interest Down 13.1% in March

VolitionRx Limited (NYSEAMERICAN:VNRX) was the target of a large decline in short interest in the month of March. As of March 15th, there was short interest totalling 507,400 shares, a decline of 13.1% from the February 28th total of 583,700 shares. Based on an average daily volume of 123,100 shares, the short-interest ratio is currently 4.1 days. Currently, 0.9% of the shares of the company are short sold.

VolitionRx Stock Performance

VolitionRx stock traded up $0.01 during mid-day trading on Thursday, reaching $0.55. 21,751 shares of the stock traded hands, compared to its average volume of 115,186. The stock has a market cap of $34.84 million, a PE ratio of -0.98 and a beta of 1.59. VolitionRx has a 12-month low of $0.43 and a 12-month high of $1.02.

VolitionRx Company Profile

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.